Combiwave FB200

Combiwave FB200

budesonide + formoterol


Glenmark Pharma


Uni Drug House
Concise Prescribing Info
Per actuation Formoterol fumarate dihydrate 6 mcg, budesonide 200 mcg
Regular treatment of persistent asthma where use of combination of inhaled corticosteroid plus bronchodilator is appropriate.
Dosage/Direction for Use
Adult & adolescent >12 yr 1-2 inhalation bd.
Hypersensitivity. Primary treatment of status asthmaticus or other acute episodes of asthma or COPD.
Special Precautions
Asthma-related death, acutely deteriorating asthma & treatment of acute symptoms. CV or CNS disorders. Convulsive disorders, thyrotoxicosis, DM & ketoacidosis. Combination w/ additional long-acting β2-agonist & strong CYP450 3A4 inhibitors. Monitor for signs of oral cavity & lung infections. Close monitoring is warranted for glaucoma & cataracts. Potential worsening of infections. Taper slowly if transferring from systemic corticosteroids. Hypercorticism & adrenal suppresion. Discontinue use in paradoxical bronchospasm. Assess bone mineral density initially & periodically thereafter. Hypoglycemia & hyperglycemia. Monitor growth in childn. Pregnancy & lactation.
Adverse Reactions
Formoterol: Tremor, palpitations & headache. Budesonide: Hoarseness, oral & systemic candidiasis.
Drug Interactions
Increased plasma levels of orally ingested budesonide w/ ketoconazole.
ATC Classification
R03AK07 - formoterol and budesonide ; Belongs to the class of adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics. Used in the treatment of obstructive airway diseases.
Combiwave FB200 inhaler
150 metered dose x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in